All In Biotech

Drug Trial Radar · NCT03459534

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

A Phase 3 Multinational, Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Ph+ Chronic Phase Chronic Myeloid Leukemia Patients With Failure or Intolerance to Previous TKIs Therapy Including Imatinib

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

173

Planned (sponsor's estimate)

Start

Jun 25, 2018

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In a multinational, multicenter, single-arm, open-label and Phase III Radotinib clinical study, chronic phase Ph+ chronic myeloid leukemia patients with failure or intolerance to previous TKIs therapy including Imatinib will be recruited. In this phase 3 study, 173 subjects are expected to be enrolled in a single arm with the administration of Radotinib 400mg twice daily, which includes 10% of dropout rate.

Conditions

  • Chronic Myeloid Leukemia, Chronic Phase
  • CML, Chronic Phase
  • CML, Refractory
  • CML - Philadelphia Chromosome

Interventions

  • Radotinib HClDrug

    1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd. 2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib) 3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder 4. Storage conditions: Store in an airtight light proof container at room temperature.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Cytogenetic Response (MCyR)Time frame: at month 6

Locations

18 sites in 4 countries. Site status is shown where the registry gives one.

  • Territorial State Budgetary Institution

    Barnaul, Russia · Not yet recruiting

  • Federal State Budgetary Institution of Science

    Kirov, Russia · Recruiting

  • Federal State Budgetary Institution

    Moscow, Russia · Not yet recruiting

  • Hematology Centre based on City Clin. Hosp. n.a. S.P. Botkin

    Moscow, Russia · Recruiting

  • Federal State Budgetary Institution

    Saint Petersburg, Russia · Recruiting

  • Federal State Budgetary Institution

    Saint Petersburg, Russia · Recruiting

  • Uijeongbu Eulji Medical Center, Eulji University

    Uijeongbu-si, Gyeonggi-do, South Korea · Recruiting

  • Ankara University Medical Faculty

    Ankara, Turkey (Türkiye) · Recruiting

  • Gazi University Medical Faculty

    Ankara, Turkey (Türkiye) · Recruiting

  • Istanbul University Cerrahpasa - Cerrahpasa Medical Faculty

    Istanbul, Turkey (Türkiye) · Recruiting

  • Ege University Medical Faculty

    Izmir, Turkey (Türkiye) · Recruiting

  • Mersin University Medical Faculty

    Mersin, Turkey (Türkiye) · Recruiting

  • Ondokuz Mayis Univ. Med. Fac.

    Samsun, Turkey (Türkiye) · Recruiting

  • CI Cherkasy Regional Oncological Dispensary of CRC

    Cherkassy, Ukraine · Recruiting

  • CTPI Chernihiv Regional Oncological Dispensary

    Chernihiv, Ukraine · Recruiting

  • CI Dnipropetrovsk CMCH #4 OF Dnipropetrovsk RC

    Dnipro, Ukraine · Recruiting

  • Institute of CR of SI NSC of Radiation Medicine of NAMSU H&T Unit

    Kyiv, Ukraine · Recruiting

  • SI Institute of Blood Pathology and Transfusion Medicine of AMSU

    Lviv, Ukraine · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.